TA 993

Drug Profile

TA 993

Latest Information Update: 17 Feb 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanabe Seiyaku
  • Class Antiplatelets
  • Mechanism of Action Calcium channel antagonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Peripheral arterial occlusive disorders

Most Recent Events

  • 17 Feb 2004 This compound is still in active development
  • 25 Nov 2003 This compound is still in active development
  • 27 Jan 2000 A preclinical study has been added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top